

ATEZOLIZUMAB IN METASTATIC LUNG CANCER – CURRENT EVIDENCE

Libor Havel

Dpt. of Pneumology, First Medical Faculty, Charles University, Prague, Czech Republic

Immunotherapy became after 2015 an inseparable part of lung cancer treatment, especially drugs blocking PD-1 /PD-L1 pathway. Atezolizumab is a humanized IgG1 antibody that binds PD-L1, preventing its interaction with PD-1 and B7-1. Preventing the interaction of PD-L1 and PD-1 removes inhibition of immune responses such as the anti-tumor immune response but not antibody dependent cellular cytotoxicity. Presentation describes atezolizumab clinical development in lung cancer, both small-cell and non-small-cell histologies. The most important registrational trials changing clinical practice will be presented.